Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 686-694

  Mencacci, Antonella ^a   Cenci, Elio ^a   Bacci, Angela ^a   Bistoni, Francesco ^a   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; BIOZOLENE; FLUCONAZOLE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 12; SXC 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; LEUKOPENIA; LYMPHOCYTE ACTIVATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIBODIES, MONOCLONAL; CANDIDA ALBICANS; CANDIDIASIS; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; FLUCONAZOLE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-12; KIDNEY; MICE; MICE, INBRED BALB C; RECEPTORS, INTERLEUKIN-4; RECOMBINANT PROTEINS; RNA, MESSENGER; TH1 CELLS;

EID: 0034056344     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315277     Document Type: Article

References (60)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20:1526-30.
2. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-9.
3. Sheehan DJ, Hitchcoke CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12:40-79.
4. Alexander BA, Perfect JR. Antifungal resistance trends towards the year 2000: implications for therapy and new approaches. Drugs 1997; 54:657-78.
5. Polonelli L, Cassone A. Novel strategies for treating candidiasis. Curr Opin Infect Dis 1999; 12:61-6.
6. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10:477-504.
7. Walsh TJ, Lee JW, Roilides E, et al. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis 1992; 14(Suppl 1):S139-47.
8. Hay RJ. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother 1991; 28(Suppl B):27-38.
9. Van 't Wout JW, Mattie H, van Furth R. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob Agents Chemother 1989; 33:147-51.
10. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26:1266-9.
11. Roilides E, Dignani MC, Anaissie EJ, Rex JH. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 1998; 36(Suppl 1):12-25.
12. Romani L, Howard DH. Mechanisms of resistance to fungal infections. Curr Opin Immunol 1995; 7:517-23.
13. Romani L, Puccetti P, Bistoni F. Biological role of helper T-cell subsets in candidiasis. Chem Immunol 1996; 63:115-37.
14. Romani L, Bistoni F, Puccetti P. Initiation of T helper cell immunity to Candida albicans by IL-12: the role of neutrophils. Chem Immunol 1997; 68:110-35.
15. + T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun 1996; 64:4907-14.
16. Cenci E, Mencacci A, Del Sero G, Bistoni F, Romani L. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist. J Infect Dis 1997; 176:217-26.
17. + subset expression in murine candidiasis. Infect Immun 1992; 60:4950-2.
18. Cenci E, Mencacci A, Del Sero G, et al. IFN-γ is required for IL-12 responsiveness in mice with Candida albicans infection. J Immunol 1998; 161:3543-50.
19. Spaccapelo R, Romani L, Tonnetti L, et al. TGF-β is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. J Immunol 1995; 155:1349-60.
20. + T helper cell 1 development in interleukin-6 -deficient mice infected with Candida albicans. J Exp Med 1996; 183:1345-55.
21. b1 development in tumor necrosis factor/lymphotoxin-α double-deficient mice infected with Candida albicans. Int Immunol 1998; 10:37-48.
22. Romani L, Mencacci A, Tonnetti L, et al. Interleukin-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. J Immunol 1994; 153:5167-75.
23. Romani L, Mencacci A, Grohmann U, et al. Neutralizing antibody to interleukin-4 induces systemic protection and T helper type 1 associated immunity in murine candidiasis. J Exp Med 1992; 176:19-25.
24. Puccetti P, Mencacci A, Grohmann U, et al. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis 1994; 169:1325-31.
25. Tonnetti L, Spaccapelo R, Cenci E, et al. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol 1995; 25:1559-65.
26. Romani L, Puccetti P, Mencacci A, et al. Neutralization of IL-10 upregulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. J Immunol 1994; 152:3514-21.
27. Romani L, Bistoni F, Mencacci A, Cenci E, Spaccapelo R, Puccetti P. IL-12 in Candida albicans infections. Res Immunol 1995; 146:532-8.
28. + T helper subset selection in mice with candidiasis. J Immunol 1997; 158:2356-62.
29. Anaissie EJ, Karyotakis NC, Hachem R, Dignami MC, Rex JH, Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994; 170:384-9.
30. Yamaguchi H, Abe S, Tokuda Y. Immunomodulating activity of antifungal drugs. Ann N Y Acad Sci 1993; 685:447-57.
31. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16:51-5.
32. Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol 1998; 149:478-88.
33. Huang S, Hendriks W, Althage A, et al. Immune response in mice that lack the interferon-γ receptor. Science 1993; 259:1742-5.
34. Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethmann H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362:245-8.
35. Bistoni F, Baccarini M, Blasi E, Marconi P, Puccetti P, Garaci E. Correlation between in vivo and in vitro studies of modulation of resistance to experimental Candida albicans infection by cyclophosphamide in mice. Infect Immun 1983; 40:46-55.
36. Rogers HW, Unanue ER. Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect Immun 1993; 61:5090-6.
37. Romani L, Mencacci A, Cenci E, et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997; 158:5349-56.
38. + T helper type 1 cell responses to Candida albicans. J Exp Med 1998; 187:307-17.
39. Rogers PD, Jenkins JK, Chapman SW, Ndebele K, Chapman BA, Cleary JD. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 1998; 178:1726-33.
40. Chia JKS, Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis 1989; 159:113-6.
41. Vonk AG, Netea MG, Denecker NE, Verschueren IC, van der Meer JW, Kullberg BJ. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J Antimicrob Chemother 1998; 42:469-74.
42. Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998; 42:2467-73.
43. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 1991; 34:205-15.
44. Bistoni F, Vecchiarelli A, Mazzolla R, Puccetti P, Marconi P, Garaci E. Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother 1985; 27:625-31.
45. Blanke TJ, Little JR, Shirley SF, Lynch RG. Augmentation of murine immune responses by amphotericin B. Cell Immunol 1977; 33:180-90.
46. Sullivan GW, Carper HT, Mandell GL. Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro. Antimicrob Agents Chemother 1992; 36:408-16.
47. Roilides E, Walsh TJ, Rubin M, Venzon B, Pizzo PA. Effects of antifungal agents on the function of human neutrophils in vitro. Antimicrob Agents Chemother 1990; 34:196-201.
48. Edwards JE, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis 1992; 14(Suppl 1):S106-13.
49. Louie A, Baltch AL, Smith RP, et al. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis. J Infect Dis 1995; 171:406-15.
50. Brummer E, Hanson LH, Stevens DA. IL-4, IgE, and gamma-interferon production in pulmonary blastomycosis: comparison in mice untreated, immunized, or treated with an antifungal (SCH 39304). Cell Immunol 1993; 149:258-67.
51. Hostetler JS, Brummer E, Coffman RL, Stevens DA. Efficacy of anti IL-4, interferon-gamma, and an antifungal triazole (SCH 42427) in chronic paracoccidioidomycosis: IgE levels correlated with outcome. Clin Exp Immunol 1993; 94:11-6.
52. Clemons KV, Brummer E, Stevens DA. Cytokine treatment in central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38:460-4.
53. Van Etten EW, van De Rhee NE, van Kampen KM, Bakker-Woudenberg IA. Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans. Antimicrob Agents Chemother 1991; 35:2275-81.
54. Van 'T Wout JW, Meynaar I, Linde I, Mattie H, van Furth R. Effect of amphotericin B, fluconazole and itraconazole on intracellular C. albicans and germ tube development in macrophages. J Antimicrob Chemother 1990; 25:803-11.
55. Ha CK, White TC. Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 1999; 43:763-8.
56. Kobayashi SD, Cutler JE. Candida albicans hyphal formation and virulence: is there a clearly defined role? Trends Microbiol 1998; 6:92-4.
57. Mencacci A, Cenci E, Del Sero G, et al. IL-10 is required for development of protective Th1 responses in IL-12 deficient mice upon Candida albicans infection. J Immunol 1998; 161:6228-37.
58. Romani L. Immunity to Candida albicans: Th1, Th2 cells and beyond. Curr Opin Microbiol 1999; 2:363-7.
59. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170:1331-4.
60. Lutz JE, Clemons KV, Stevens DA. Synergy between interferon-gamma and antifungal chemotherapy in experimental cryptococcosis [abstract 217 of the ISDA 34th Annual Meeting]. Clin Infect Dis 1996; 23:899.